急性冠状动脉综合征的抗血栓治疗:新的临床指南，有争议的问题和院前分期的作用

Q4 Medicine

Sklifosovsky Journal Emergency Medical Care Pub Date : 2022-01-19 DOI:10.24884/2072-6716-2021-22-4-4-11

V. Shalnev, N. Petrova, I. Y. Lukianova

{"title":"急性冠状动脉综合征的抗血栓治疗:新的临床指南，有争议的问题和院前分期的作用","authors":"V. Shalnev, N. Petrova, I. Y. Lukianova","doi":"10.24884/2072-6716-2021-22-4-4-11","DOIUrl":null,"url":null,"abstract":"Antithrombotic therapy is a cornerstone of acute coronary syndromes treatment, preventing coronary artery thrombosis development and progression. Early administration of P2Y12 receptor antagonists to patients with acute coronary syndromes (ACS) at the prehospital stage is a common practice and has been supported by the European and Russian Societies of Cardiology guidelines for many years despite the lack of definite evidence for its benefit. Recent clinical trials and registers on ACS treatment have shown no benefit and higher prevalence of bleeding related to the early start of P2Y12 receptor antagonists in NSTE-ACS patients. The latest European and Russian Societies of Cardiology guidelines do not recommend prehospital administration of P2Y12 receptor antagonists. The article highlights the antithrombotic therapy in acute coronary syndromes setting, recent ESC guidelines and its possible implementation in common practice.","PeriodicalId":37398,"journal":{"name":"Sklifosovsky Journal Emergency Medical Care","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antithrombotic therapy in acute coronary syndromes setting: new clinical guidelines, controversial issues and the role of prehospital stage\",\"authors\":\"V. Shalnev, N. Petrova, I. Y. Lukianova\",\"doi\":\"10.24884/2072-6716-2021-22-4-4-11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antithrombotic therapy is a cornerstone of acute coronary syndromes treatment, preventing coronary artery thrombosis development and progression. Early administration of P2Y12 receptor antagonists to patients with acute coronary syndromes (ACS) at the prehospital stage is a common practice and has been supported by the European and Russian Societies of Cardiology guidelines for many years despite the lack of definite evidence for its benefit. Recent clinical trials and registers on ACS treatment have shown no benefit and higher prevalence of bleeding related to the early start of P2Y12 receptor antagonists in NSTE-ACS patients. The latest European and Russian Societies of Cardiology guidelines do not recommend prehospital administration of P2Y12 receptor antagonists. The article highlights the antithrombotic therapy in acute coronary syndromes setting, recent ESC guidelines and its possible implementation in common practice.\",\"PeriodicalId\":37398,\"journal\":{\"name\":\"Sklifosovsky Journal Emergency Medical Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sklifosovsky Journal Emergency Medical Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24884/2072-6716-2021-22-4-4-11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sklifosovsky Journal Emergency Medical Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24884/2072-6716-2021-22-4-4-11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

抗血栓治疗是急性冠状动脉综合征治疗的基石，可预防冠状动脉血栓形成和进展。在院前阶段对急性冠脉综合征(ACS)患者早期给予P2Y12受体拮抗剂是一种常见的做法，尽管缺乏明确的证据，但多年来一直得到欧洲和俄罗斯心脏病学会指南的支持。最近关于ACS治疗的临床试验和登记显示，在NSTE-ACS患者中，早期使用P2Y12受体拮抗剂没有任何益处，而且出血发生率较高。最新的欧洲和俄罗斯心脏病学会指南不建议院前给药P2Y12受体拮抗剂。本文重点介绍急性冠状动脉综合征的抗血栓治疗，最近的ESC指南及其在普通实践中的可能实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Antithrombotic therapy in acute coronary syndromes setting: new clinical guidelines, controversial issues and the role of prehospital stage

Antithrombotic therapy is a cornerstone of acute coronary syndromes treatment, preventing coronary artery thrombosis development and progression. Early administration of P2Y12 receptor antagonists to patients with acute coronary syndromes (ACS) at the prehospital stage is a common practice and has been supported by the European and Russian Societies of Cardiology guidelines for many years despite the lack of definite evidence for its benefit. Recent clinical trials and registers on ACS treatment have shown no benefit and higher prevalence of bleeding related to the early start of P2Y12 receptor antagonists in NSTE-ACS patients. The latest European and Russian Societies of Cardiology guidelines do not recommend prehospital administration of P2Y12 receptor antagonists. The article highlights the antithrombotic therapy in acute coronary syndromes setting, recent ESC guidelines and its possible implementation in common practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sklifosovsky Journal Emergency Medical Care Medicine-Emergency Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The Journal "Neotlozhnaia meditsinskaia pomoshch" (parallel titles: Zhurnal im. N.V. Sklifosovskogo "Neotlozhnai︠a︡ medit︠s︡inskai︠a︡ pomoshch", "Sklifosovsky Journal of Emergency Medical Care") seeks to publish original research articles, literature reviews, case reports, brief reports on clinical practice, and other suitable material submitted by professionals involved in the diagnosis and treatment of acute medical and surgical conditions.